

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				COMPLETE IF KNOWN	
				Application Number	10/537,758
				Filing Date	June 6, 2005
				First Named Inventor	Mark E. Fraley
				Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned				
Sheet	1	of	1	Attorney Docket Number	20977P

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
VB	1	Bruggen, N.V., et al., "VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain", The Journal of Clinical Investigation, Vol. 104, pp 1613-1620 (1999)
VB	2	Deckers, M.M.L., et al., "Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation", Endocrinology, Vol. 141, pp. 1667-1674 (2000)
VB	3	Fraley, M. E., et al., "Optimization of a Pyrazolo[1,5-alpyrimidine Class of KDR Kinase Inhibitors: Improvements in Physical Properties Enhance Cellular Activity and Pharmacokinetics", Bioorganic & Medicinal Chemistry Letters, Vol 12, pp. 3537-3541 (2002)
VB	4	Fraley, M.E., et al., "Property-Based Design of KDR Kinase Inhibitors", Current Medicinal Chemistry, Vol. 11, pp. 709-719 (2004)
VB	5	Fraley, M.E., et al., "Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-alpyrimidines: A New Class of KDR Kinase Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 12, pp. 2767-2770, (2002)
VB	6	Gerber, H.P., et al., "VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation", Nature Medicine, Vol. 5, pp. 623-628 (1999)
VB	7	Greenberg, D.A., et al., "Angiogenesis and Stroke", Drug News Perspect, Vol. 11, pp. 265-270 (1998)
VB	8	Hasegawa, T., et al., "Intracortical osteoblastic osteosarcoma with oncogenic rickets", Skeletal Radiology, Vol. 28, pp. 41-45 (1999)
VB	9	Nakagawa, M., et al., "Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts", FEBS Letters, Vol. 473, pp. 161-164 (2000)
VB	10	Paul, R. et al., "Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke", Nature Medicine, Vol. 7, pp. 222-227 (2001)
VB	11	Rak, J., et al., "Mutant ras Oncogenes Upregulate VEGF/FPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis", Cancer Research, Vol. 55, pp. 4575-4580 (1995)

Examiner Signature	/Venkataraman Balasubramanian/	Date Considered	09/29/2006
--------------------	--------------------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449A/PTO **SUPPLEMENTAL
INFORMATION DISCLOSURE**

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

COMPLETE IF KNOWN

Application Number	10/537,758
Filing Date	June 6, 2005
First Named Inventor	Mark E. Fraley
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	20977P

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

V Balasubramaniam

**Date
Considered**

9/29/86

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2003